AI has started making drug-like antibodies. When will it revolutionize biopharma?

Taking stock of the drug industry, from the lab to the medicine chest

January 6, 2026 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | AI has finally started making drug-like antibodies. When will it revolutionize biopharma? AI can now design drug-like antibodies, but even biotech executives embracing the new tech say traditional wet lab techniques still have a very important role to play. By Brittany Trang STAT+ | Arrowhead's gene-silencing drugs cut fat in early obesity studies In an early study, patients who took two doses of ARO-INHBE combined with Eli Lilly's Zepbound lost 9.4% of their weight after 16 weeks. By Elaine Chen New vaccine schedule adds near- and long-term risks for children, experts warn Pediatricians explain how changes to the childhood vaccine schedule could affect clinic visits, insurance coverage, school requirements, and children's health. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser